恩替卡韦对慢性乙型肝炎患者肝功能的近期影响  

Influence of entecavir on hepatic function of chronic hepatitis B in the near future

作　　者：黄文琪[1] 张玲霞[2] 宋闽宁[1] 闵峰[1] 张丽[1] 吴卫兵[1] 范荣华[1] 

机构地区：[1]中国人民解放军第174医院感染科,福建厦门361003 [2]中国人民解放军第302医院

出　　处：《中西医结合肝病杂志》2007年第3期142-143,共2页Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases

摘　　要：目的:研究恩替卡韦对慢性乙型肝炎患者肝功能ALT的近期影响。方法:观察恩替卡韦联合保肝药物与单用一般保肝药物治疗慢性乙型肝炎第4、8、12周症状、体征、肝功能ALT变化及HBV DNA转阴情况。结果:两组患者在治疗第4、8、12周,症状及体征均基本缓解,差异无显著性意义(P>0.05);治疗组患者在第4周ALT显著高于对照组(P<0.01),在第12周显著低于对照组(P<0.05);第4周时治疗组ALT反弹率显著高于对照组(P<0.01);治疗组在第4、8、12周HBV DNA转阴率均显著高于对照组(P<0.01)。结论:恩替卡韦治疗慢性乙型肝炎患者近期肝功能可出现一过性ALT升高,部分患者ALT反弹。恩替卡韦抗HBV复制效果显著。Objective： To study the influence of entecavir on hepatic function chronic hepatitis B in the near future. Methods： Changes of ALT, HBV DNA, symptom, objective sign mutation of 60 patients at 4, 8, 12 weeks before and after entecavir were determined. Results： Two groups patients＇ symptom and objective sign were fundamental relief and showed no significant （P 〉 0. 05 ） ; the ALT of treated group showed great significant than control group at 4 weeks （P 〈 0. 01 ）, the ALT of treated group showed great significant lesser than control group at 12 weeks （P 〈 0. 05 ）, the ALT of treated group were increased prominently and showed great significant higher than control group at 4 weeks （ P 〈 0. 01 ）, HBV DNA mutation of treated group showed great significant higher than control group at 4, 8, 12 weeks （P 〈 0. 01 ）. Conclusion： Entecavir is effective though the mutations and breakthrough are present.

关 键 词：恩替卡韦/治疗应用 肝炎 乙型 慢性 肝功能 

分 类 号：R512.6[医药卫生—内科学]